JP2018529634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529634A5 JP2018529634A5 JP2018501163A JP2018501163A JP2018529634A5 JP 2018529634 A5 JP2018529634 A5 JP 2018529634A5 JP 2018501163 A JP2018501163 A JP 2018501163A JP 2018501163 A JP2018501163 A JP 2018501163A JP 2018529634 A5 JP2018529634 A5 JP 2018529634A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- monoclonal antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 60
- 239000000427 antigen Substances 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 47
- 208000018737 Parkinson disease Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 10
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 10
- 208000015872 Gaucher disease Diseases 0.000 claims description 6
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 6
- 208000032859 Synucleinopathies Diseases 0.000 claims description 6
- 210000004558 lewy body Anatomy 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002567 autonomic effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 description 25
- 108090000185 alpha-Synuclein Proteins 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001690 micro-dialysis Methods 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 102000019355 Synuclein Human genes 0.000 description 2
- 108050006783 Synuclein Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021136539A JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2022136108A JP7608404B2 (ja) | 2015-07-13 | 2022-08-29 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2024221962A JP2025041734A (ja) | 2015-07-13 | 2024-12-18 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512203.9A GB201512203D0 (en) | 2015-07-13 | 2015-07-13 | Agents,uses and methods |
| GB1512203.9 | 2015-07-13 | ||
| PCT/EP2016/066476 WO2017009312A1 (en) | 2015-07-13 | 2016-07-12 | Agents, uses and methods for the treatment of synucleinopathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021136539A Division JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529634A JP2018529634A (ja) | 2018-10-11 |
| JP2018529634A5 true JP2018529634A5 (enExample) | 2019-08-15 |
| JP7012004B2 JP7012004B2 (ja) | 2022-02-10 |
Family
ID=54013851
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501163A Active JP7012004B2 (ja) | 2015-07-13 | 2016-07-12 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2021136539A Active JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2022136108A Active JP7608404B2 (ja) | 2015-07-13 | 2022-08-29 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2024221962A Pending JP2025041734A (ja) | 2015-07-13 | 2024-12-18 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021136539A Active JP7138322B2 (ja) | 2015-07-13 | 2021-08-24 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2022136108A Active JP7608404B2 (ja) | 2015-07-13 | 2022-08-29 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| JP2024221962A Pending JP2025041734A (ja) | 2015-07-13 | 2024-12-18 | シヌクレイノパチーの治療のための薬剤、使用および方法 |
Country Status (41)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| AU2017359944B2 (en) * | 2016-11-15 | 2024-07-18 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| ES3008133T3 (en) | 2016-12-16 | 2025-03-21 | H Lundbeck As | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| MX2019008029A (es) | 2017-01-06 | 2019-12-11 | Abl Bio Inc | Anticuerpo anti-alfa-sinucleina y su uso. |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| US10799484B2 (en) * | 2017-03-27 | 2020-10-13 | Chase Therapeutics Corporation | Compositions and methods for treating synucleinopathies |
| IL270361B2 (en) | 2017-05-01 | 2025-04-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| US11155608B2 (en) | 2017-08-23 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
| KR102508933B1 (ko) * | 2017-11-17 | 2023-03-13 | 에이비엘바이오 주식회사 | 알파-시누클레인에 대한 항체 및 그 용도 |
| CN116731173A (zh) | 2017-12-14 | 2023-09-12 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| MX2020007904A (es) | 2018-01-26 | 2020-09-07 | Quantum Si Inc | Llamado de pulso y base habilitado por maquina de aprendizaje para dispositivos de secuenciacion. |
| EP3752840A4 (en) * | 2018-02-12 | 2022-08-10 | The Scripps Research Institute | PROCEDURES RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES |
| WO2020033756A1 (en) * | 2018-08-09 | 2020-02-13 | F. Hoffmann-La Roche Ag | Determination of parkinson's disease |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| WO2020212593A1 (en) * | 2019-04-18 | 2020-10-22 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| EP3962492A4 (en) * | 2019-04-29 | 2023-05-31 | Thomas Jefferson University | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| JP2023504699A (ja) * | 2019-12-04 | 2023-02-06 | エイシー イミューン ソシエテ アノニム | 治療および診断のための新規な分子 |
| KR102466943B1 (ko) * | 2020-04-02 | 2022-11-14 | 한국과학기술연구원 | 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템 |
| CN111537738A (zh) * | 2020-05-18 | 2020-08-14 | 南通大学附属医院 | 用于超早期帕金森病检测的试剂盒 |
| KR20240055785A (ko) * | 2021-09-01 | 2024-04-29 | 백시니티, 인크. | 시누클레인병증의 방지 및 치료 방법 |
| IL311344A (en) | 2021-09-16 | 2024-05-01 | H Lundbeck As | Preparations and methods for the treatment of synoclinopathies |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| WO2024177999A2 (en) * | 2023-02-21 | 2024-08-29 | The Regents Of The University Of Michigan | Human aggregated alpha-synuclein binding molecules |
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
| WO2025076635A1 (en) * | 2023-10-12 | 2025-04-17 | Universite Laval | Anti-alpha-synuclein antibodies and uses thereof |
| WO2025186235A1 (en) | 2024-03-05 | 2025-09-12 | H. Lundbeck A/S | Compositions and methods for treating multiple system atrophy (msa) |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1512203A (en) | 1974-05-08 | 1978-05-24 | Aspin F | Rolls for use in profiling film |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988004777A1 (en) | 1986-12-15 | 1988-06-30 | Ultra Diagnostics Corporation | Monomeric phthalocyanine reagents |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CN1440420A (zh) | 2000-07-07 | 2003-09-03 | 万能药制药公司 | 预防神经组织损伤和治疗α－共核蛋白疾病的方法 |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| WO2003000714A2 (en) | 2001-06-22 | 2003-01-03 | Panacea Pharmaceuticals, Inc. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US8829198B2 (en) | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| DK1633189T3 (en) | 2003-05-19 | 2017-08-21 | Prothena Biosciences Ltd | TRUNCTED FRAGMENTS OF ALFA SYNUCLEIN IN LEWY BODY DISEASE |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2006031250A (ja) | 2004-07-14 | 2006-02-02 | Fuji Xerox Co Ltd | 通信装置およびその制御方法 |
| EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
| US20060205024A1 (en) | 2005-03-08 | 2006-09-14 | Sun Health Research Institute | Method to diagnose and evaluate progression of Alzheimer's disease |
| US20080300204A1 (en) * | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| PT3067066T (pt) | 2007-02-23 | 2019-06-17 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
| DK3067066T3 (da) | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
| HUE027278T2 (en) * | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| WO2010069603A1 (en) * | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| WO2010118282A1 (en) | 2009-04-09 | 2010-10-14 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| GB201008682D0 (en) | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| LT2723379T (lt) * | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
| JP2013059866A (ja) | 2011-09-12 | 2013-04-04 | Seiko Epson Corp | 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム |
| LT2771031T (lt) * | 2011-10-28 | 2018-08-27 | Prothena Biosciences Limited | Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną |
| WO2014008404A1 (en) | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9855276B2 (en) | 2012-10-25 | 2018-01-02 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CA2924268C (en) * | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| MX2017014191A (es) | 2015-05-07 | 2018-08-01 | Axovant Sciences Gmbh | Metodos de tratamiento de una enfermedad neurodegenerativa. |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| KR102499438B1 (ko) | 2016-06-02 | 2023-02-14 | 메디뮨 리미티드 | 알파-시누클레인에 대한 항체 및 이의 용도 |
| AU2017359944B2 (en) | 2016-11-15 | 2024-07-18 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
-
2015
- 2015-07-13 GB GBGB1512203.9A patent/GB201512203D0/en not_active Ceased
-
2016
- 2016-07-11 JO JOP/2016/0140A patent/JO3692B1/ar active
- 2016-07-12 KR KR1020257011170A patent/KR20250051158A/ko active Pending
- 2016-07-12 MY MYPI2017001926A patent/MY194944A/en unknown
- 2016-07-12 JP JP2018501163A patent/JP7012004B2/ja active Active
- 2016-07-12 ES ES16738736T patent/ES3028882T3/es active Active
- 2016-07-12 AU AU2016292896A patent/AU2016292896B2/en active Active
- 2016-07-12 EA EA201792616A patent/EA036499B1/ru not_active IP Right Cessation
- 2016-07-12 TW TW105121902A patent/TWI729992B/zh active
- 2016-07-12 GE GEAP201614670A patent/GEP20207151B/en unknown
- 2016-07-12 MA MA42439A patent/MA42439B1/fr unknown
- 2016-07-12 HR HRP20250624TT patent/HRP20250624T1/hr unknown
- 2016-07-12 LT LTEPPCT/EP2016/066476T patent/LT3322722T/lt unknown
- 2016-07-12 CA CA2989735A patent/CA2989735A1/en active Pending
- 2016-07-12 CN CN202210997939.4A patent/CN115925921A/zh active Pending
- 2016-07-12 RU RU2017145653A patent/RU2765303C2/ru active
- 2016-07-12 PL PL16738736.4T patent/PL3322722T3/pl unknown
- 2016-07-12 US US15/207,859 patent/US10800836B2/en active Active
- 2016-07-12 CR CR20230300A patent/CR20230300A/es unknown
- 2016-07-12 EP EP16738736.4A patent/EP3322722B1/en active Active
- 2016-07-12 PT PT167387364T patent/PT3322722T/pt unknown
- 2016-07-12 TN TNP/2018/000005A patent/TN2018000005A1/en unknown
- 2016-07-12 CR CR20180021A patent/CR20180021A/es unknown
- 2016-07-12 SI SI201631902T patent/SI3322722T1/sl unknown
- 2016-07-12 CN CN201680039417.6A patent/CN107709361A/zh active Pending
- 2016-07-12 UA UAA201800664A patent/UA125501C2/uk unknown
- 2016-07-12 KR KR1020177037733A patent/KR102793383B1/ko active Active
- 2016-07-12 HU HUE16738736A patent/HUE071541T2/hu unknown
- 2016-07-12 AR ARP160102110A patent/AR105336A1/es unknown
- 2016-07-12 EP EP25154059.7A patent/EP4582144A3/en active Pending
- 2016-07-12 RS RS20250497A patent/RS66840B1/sr unknown
- 2016-07-12 WO PCT/EP2016/066476 patent/WO2017009312A1/en not_active Ceased
- 2016-07-12 DK DK16738736.4T patent/DK3322722T3/da active
- 2016-07-12 FI FIEP16738736.4T patent/FI3322722T3/fi active
- 2016-07-12 MX MX2018000504A patent/MX2018000504A/es unknown
- 2016-07-12 PE PE2018000066A patent/PE20181049A1/es unknown
-
2017
- 2017-11-14 US US15/812,363 patent/US10364285B2/en active Active
- 2017-11-14 US US15/812,251 patent/US10358482B2/en active Active
- 2017-11-14 US US15/812,303 patent/US10358483B2/en active Active
- 2017-11-14 US US15/812,410 patent/US10358484B2/en active Active
- 2017-12-15 CO CONC2017/0012941A patent/CO2017012941A2/es unknown
- 2017-12-18 ZA ZA2017/08607A patent/ZA201708607B/en unknown
- 2017-12-22 IL IL256501A patent/IL256501B/en unknown
-
2018
- 2018-01-03 PH PH12018500016A patent/PH12018500016A1/en unknown
- 2018-01-09 CL CL2018000075A patent/CL2018000075A1/es unknown
- 2018-01-11 NI NI201800006A patent/NI201800006A/es unknown
- 2018-01-11 SV SV2018005612A patent/SV2018005612A/es unknown
- 2018-01-11 DO DO2018000013A patent/DOP2018000013A/es unknown
- 2018-01-12 EC ECIEPI20182645A patent/ECSP18002645A/es unknown
- 2018-01-12 MX MX2023009483A patent/MX2023009483A/es unknown
-
2019
- 2019-06-17 US US16/443,225 patent/US10647764B2/en active Active
- 2019-06-17 US US16/443,249 patent/US10640554B2/en active Active
- 2019-06-17 US US16/443,187 patent/US10647763B2/en active Active
-
2020
- 2020-06-08 US US16/895,471 patent/US11524995B2/en active Active
- 2020-08-27 US US17/004,447 patent/US11421024B2/en active Active
- 2020-11-03 US US17/088,307 patent/US11542323B2/en active Active
-
2021
- 2021-08-24 JP JP2021136539A patent/JP7138322B2/ja active Active
-
2022
- 2022-08-29 JP JP2022136108A patent/JP7608404B2/ja active Active
- 2022-11-22 US US17/992,403 patent/US20230312693A1/en active Pending
-
2024
- 2024-12-18 JP JP2024221962A patent/JP2025041734A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529634A5 (enExample) | ||
| RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| JP5896993B2 (ja) | ヒトｇｄｆ８に対する抗体 | |
| JP5730020B2 (ja) | アミロイドーシスの処置および予防 | |
| KR102308493B1 (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2021184731A5 (enExample) | ||
| KR102533675B1 (ko) | 타우 인식 항체 | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| CN109219615A (zh) | 识别tau的抗体 | |
| JP2017522903A5 (enExample) | ||
| SA515360253B1 (ar) | أجسام مضادة مُميزة لألفا سينوكلين | |
| US20100215650A1 (en) | Methods of treating dementia using a gm-csf antagonist | |
| CN102089430A (zh) | 针对渐进性糖化终极产物受体（rage）的抗体及其用途 | |
| JP2016514668A (ja) | プロタンパク質コンベルターゼスブチリシンケクシン９型に結合するヒト抗原結合タンパク質 | |
| CN103429260B (zh) | 用于治疗神经疾病的人抗体及其诊断和治疗用途 | |
| TW201623331A (zh) | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 | |
| TW202100550A (zh) | 識別ｔａｕ之抗體 | |
| US20230030950A1 (en) | Treatment of neurodegenerative diseases using ultrasound and amyloid-beta antibodies | |
| JP2018529635A5 (enExample) | ||
| TW201121568A (en) | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof | |
| JP2020521745A (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| BR112021006123A2 (pt) | anticorpos anti-sinucleína | |
| JP2023538117A (ja) | 神経免疫疾患のためのｃｄ３／ｃｄ２５抗体 | |
| JP6560808B2 (ja) | 抗（＋）メタンフェタミンモノクローナル抗体 | |
| KR20210071987A (ko) | 항-cd79 항체 및 이들의 용도 |